Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers
暂无分享,去创建一个
J. Hokanson | R. Eckel | K. Moreau | D. Maahs | G. Kinney | M. Cree‐Green | K. Nadeau | Hong Wang | Sonali S. Patel | U. Truong | A. Ferland | Martina King | Jennifer L. Dorosz
[1] C. Kaya,et al. Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries , 2017, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[2] F. Giallauria,et al. Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial , 2016, Clinical endocrinology.
[3] J. Regensteiner,et al. Youth with type 1 diabetes have worse strain and less pronounced sex differences in early echocardiographic markers of diabetic cardiomyopathy compared to their normoglycemic peers: A RESistance to InSulin in Type 1 ANd Type 2 diabetes (RESISTANT) Study. , 2016, Journal of diabetes and its complications.
[4] Y. Taşçı,et al. The Predictive Role of Serum Cystatin C Levels in Polycystic Ovary Syndrome in Adolescents. , 2016, Journal of pediatric and adolescent gynecology.
[5] V. Štich,et al. Acute hyperlipidemia initiates proinflammatory and proatherogenic changes in circulation and adipose tissue in obese women. , 2016, Atherosclerosis.
[6] C. Fardella,et al. Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension , 2016, International journal of molecular sciences.
[7] J. Hokanson,et al. Lipoprotein subfraction cholesterol distribution is more atherogenic in insulin resistant adolescents with type 1 diabetes , 2016, Pediatric diabetes.
[8] M. Deveer,et al. Serum Copeptin, Pentraxin 3, Anti-Mullerian Hormone Levels With Echocardiography and Carotid Artery Intima-Media Thickness in Adolescents With Polycystic Ovary Syndrome , 2015, Journal of clinical medicine research.
[9] Yuan-Lin Guo,et al. Distribution of High-Density Lipoprotein Subfractions and Hypertensive Status , 2015, Medicine.
[10] Melonie P. Heron. Deaths: Leading Causes for 2012. , 2015, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[11] F. Keleştimur,et al. Metformin improves endothelial function and carotid intima media thickness in patients with PCOS , 2015, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[12] Victor Mor-Avi,et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.
[13] D. Macut,et al. Cardiovascular risk factors and events in women with androgen excess , 2015, Journal of Endocrinological Investigation.
[14] C. Lewis,et al. Prospective Association of Polycystic Ovary Syndrome With Coronary Artery Calcification and Carotid-Intima-Media Thickness: The Coronary Artery Risk Development in Young Adults Women’s Study , 2014, Arteriosclerosis, thrombosis, and vascular biology.
[15] P. Dabadghao,et al. Cardiovascular disease risk in young Indian women with polycystic ovary syndrome , 2014, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[16] Z. Allameh,et al. Does Carotid Intima-media Thickness have Relationship with Polycystic Ovary Syndrome? , 2013, International journal of preventive medicine.
[17] D. Mozaffarian,et al. Plasma Free Fatty Acids and Risk of Heart Failure: The Cardiovascular Health Study , 2013, Circulation. Heart failure.
[18] M. Hsu,et al. The relationship between carotid intima-media thickness and endogenous androgens in young women with polycystic ovary syndrome in Taiwan , 2013, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[19] M. Kleber,et al. Effect of Lifestyle Intervention on Features of Polycystic Ovarian Syndrome, Metabolic Syndrome, and Intima-Media Thickness in Obese Adolescent Girls , 2012 .
[20] M. Rewers,et al. Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes. , 2012, The Journal of clinical endocrinology and metabolism.
[21] L. Szydlowski,et al. Blood pressure regulation and resting heart rate abnormalities in adolescent girls with polycystic ovary syndrome. , 2011, Fertility and sterility.
[22] O. Dekkers,et al. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. , 2011, Human reproduction update.
[23] M. Rizzo,et al. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. , 2011, Fertility and sterility.
[24] H. Escobar-Morreale,et al. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. , 2011, Fertility and sterility.
[25] M. Rewers,et al. Association of insulin sensitivity to lipids across the lifespan in people with Type 1 diabetes , 2011, Diabetic medicine : a journal of the British Diabetic Association.
[26] M. Rewers,et al. Insulin Resistance, Defective Insulin-Mediated Fatty Acid Suppression, and Coronary Artery Calcification in Subjects With and Without Type 1 Diabetes , 2010, Diabetes.
[27] J. Hokanson,et al. Lipoprotein Subfraction Cholesterol Distribution Is Proatherogenic in Women With Type 1 Diabetes and Insulin Resistance , 2010, Diabetes.
[28] K. Cusi,et al. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects , 2010, Cardiovascular diabetology.
[29] J. Regensteiner,et al. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. , 2010, The Journal of clinical endocrinology and metabolism.
[30] A. Genazzani,et al. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. , 2009, Fertility and sterility.
[31] D. Guzick,et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. , 2008, The Journal of clinical endocrinology and metabolism.
[32] J. Marshall,et al. Polycystic Ovary Syndrome in Adolescence , 2008, Annals of the New York Academy of Sciences.
[33] E. V. van Beek,et al. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. , 2007, The Journal of clinical endocrinology and metabolism.
[34] Melonie P. Heron,et al. Deaths: leading causes for 2004. , 2007, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[35] Chi-Ling Chen,et al. Relationship Between Androgen Levels and Blood Pressure in Young Women With Polycystic Ovary Syndrome , 2007, Hypertension.
[36] M. Nery,et al. Prevalence of abnormalities of glucose metabolism in patients with polycystic ovary syndrome. , 2007, Arquivos brasileiros de endocrinologia e metabologia.
[37] D. Jacobs,et al. Influence of Insulin Resistance and Body Mass Index at Age 13 on Systolic Blood Pressure, Triglycerides, and High-Density Lipoprotein Cholesterol at Age 19 , 2006, Hypertension.
[38] C. K. Hsiao,et al. Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS. , 2006, Human reproduction.
[39] Desmond E. Williams,et al. Dietary intake among youth with diabetes: the SEARCH for Diabetes in Youth Study. , 2006, Journal of the American Dietetic Association.
[40] N. Goldenberg,et al. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents. , 2006, Metabolism: clinical and experimental.
[41] R. Legro,et al. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. , 2006, The Journal of clinical endocrinology and metabolism.
[42] H. Teede,et al. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. , 2005, The Journal of clinical endocrinology and metabolism.
[43] G. Chrousos,et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.
[44] T. Kılıç,et al. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. , 2005, Human reproduction.
[45] J. Cameron,et al. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.
[46] A. Tavridou,et al. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.
[47] Jian-Kang Chen,et al. Androgens augment proximal tubule transport. , 2004, American journal of physiology. Renal physiology.
[48] F. Orio,et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. , 2004, The Journal of clinical endocrinology and metabolism.
[49] K. Moreau,et al. Arterial intima-media thickness: site-specific associations with HRT and habitual exercise. , 2002, American journal of physiology. Heart and circulatory physiology.
[50] C. Otto,et al. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. , 2002, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[51] J. Connell,et al. Altered vascular function in young women with polycystic ovary syndrome. , 2002, The Journal of clinical endocrinology and metabolism.
[52] A. Oto,et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. , 2001, Fertility and sterility.
[53] J F Reckelhoff,et al. Gender Differences in the Regulation of Blood Pressure , 2001, Hypertension.
[54] A. Baron,et al. Polycystic Ovary Syndrome Is Associated With Endothelial Dysfunction , 2001, Circulation.
[55] S. Daya,et al. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. , 1999, Human reproduction.
[56] P A Cleary,et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. , 1998, JAMA.
[57] P S Freedson,et al. Calibration of the Computer Science and Applications, Inc. accelerometer. , 1998, Medicine and science in sports and exercise.
[58] D. Johnston,et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries , 1996, Clinical endocrinology.
[59] L. Kuller,et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[60] N. Katsilambros,et al. Relative androgenicity, blood pressure levels, and cardiovascular risk factors in young healthy women. , 1995, American journal of hypertension.
[61] S. Daniels,et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. , 1992, Journal of the American College of Cardiology.
[62] G. Conway,et al. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome , 1992, Clinical endocrinology.
[63] P Pignoli,et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. , 1986, Circulation.
[64] P. Coulson,et al. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. , 1985, The Journal of clinical endocrinology and metabolism.
[65] A. Hainline,et al. Role and methods of the central laboratory , 1983 .
[66] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[67] E. Barinas-Mitchell,et al. Early Biomarkers of Subclinical Atherosclerosis in Obese Adolescent Girls with Polycystic Ovary Syndrome. , 2016, The Journal of pediatrics.
[68] T. Kawaguchi,et al. Synergistic association of elevated serum free fatty acid and glucose levels with large arterial stiffness in a general population: The Nagahama Study. , 2016, Metabolism: clinical and experimental.
[69] H. Teede,et al. Polycystic ovary syndrome , 2016, Nature Reviews Disease Primers.
[70] Xiao-lin Li,et al. High-density lipoprotein subfractions in relation with the severity of coronary artery disease: A Gensini score assessment. , 2015, Journal of clinical lipidology.
[71] R. Wild. Polycystic ovary syndrome: a risk for coronary artery disease? , 2002, American journal of obstetrics and gynecology.
[72] S. Arslanian,et al. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. , 2001, The Journal of pediatrics.
[73] S. Arslanian,et al. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. , 2001, The Journal of clinical endocrinology and metabolism.
[74] M. Cavaghan,et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. , 1999, Diabetes care.
[75] R. Pate,et al. Validation of an instrument for measurement of physical activity in youth. , 1997, Medicine and science in sports and exercise.
[76] A. Hainline,et al. The Coronary Drug Project. Role and methods of the Central Laboratory. , 1983, Controlled clinical trials.